Jonathan W Mink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6160422/publications.pdf

Version: 2024-02-01

151 12,615 papers citations

40 h-index 107 g-index

239 all docs 239 docs citations 239 times ranked 10816 citing authors

#	Article	IF	CITATIONS
1	Risk Behaviors in Youth With and Without Tourette Syndrome. Pediatric Neurology, 2022, 126, 20-25.	2.1	4
2	The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample. European Journal of Paediatric Neurology, 2022, 38, 62-65.	1.6	3
3	Diagnostic Evaluation of Children With Movement Disorders. , 2022, , 43-67.		0
4	Hereditary Spastic Paraplegia. , 2022, , 415-440.		82
5	Tremor., 2022,, 305-331.		O
6	Ataxia. , 2022, , 333-394.		0
7	Drug-Induced Movement Disorders in Children. , 2022, , 637-666.		O
8	Basal Ganglia Anatomy, Biochemistry, and Physiology. , 2022, , 3-13.		0
9	Tics and Tourette Syndrome. , 2022, , 99-140.		1
10	Movement Disorders in Sleep. , 2022, , 561-589.		0
11	Movement Disorders in Autoimmune Diseases. , 2022, , 535-560.		O
12	Functional Movement Disorders. , 2022, , 667-679.		0
13	Motor Assessments., 2022,, 69-81.		O
14	Motor Stereotypies. , 2022, , 141-164.		0
15	Chorea, Athetosis, and Ballism., 2022, , 183-228.		O
16	Classification of Movement Disorders. , 2022, , 33-42.		0
17	Transient and Developmental Movement Disorders. , 2022, , 85-96.		O
18	Movement Disorders and Neuropsychiatric Conditions. , 2022, , 619-636.		0

#	Article	IF	Citations
19	Metabolic Disorders With Associated Movement Abnormalities. , 2022, , 443-533.		O
20	Cerebellar Anatomy, Biochemistry, Physiology, and Plasticity., 2022, , 15-32.		O
21	Myoclonus. , 2022, , 263-303.		O
22	Anxiety Symptoms Differ in Youth With and Without Tic Disorders. Child Psychiatry and Human Development, 2021, 52, 301-310.	1.9	9
23	Developing a New Set of ACGME Milestones for Child Neurology Residency. Pediatric Neurology, 2021, 114, 47-52.	2.1	4
24	A human model of Batten disease shows role of CLN3 in phagocytosis at the photoreceptor–RPE interface. Communications Biology, 2021, 4, 161.	4.4	19
25	Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet Journal of Rare Diseases, 2021, 16, 185.	2.7	17
26	Management of CLN1 Disease: International Clinical Consensus. Pediatric Neurology, 2021, 120, 38-51.	2.1	10
27	Neurophysiological biomarkers to optimize deep brain stimulation in movement disorders. Neurodegenerative Disease Management, 2021, 11, 315-328.	2.2	14
28	A diagnostic confidence scheme for <scp>CLN3</scp> disease. Journal of Inherited Metabolic Disease, 2021, 44, 1453-1462.	3.6	3
29	Academic, Interpersonal, Recreational, and Family Impairment in Children with Tourette Syndrome and Attention-Deficit/Hyperactivity Disorder. Child Psychiatry and Human Development, 2021, , 1.	1.9	13
30	Treatment of Chorea in Childhood. Pediatric Neurology, 2020, 102, 10-19.	2.1	16
31	Tic Disorders are Associated With Lower Child and Parent Quality of Life and Worse Family Functioning. Pediatric Neurology, 2020, 105, 48-54.	2.1	19
32	Movement disorders in children with congenital Zika virus syndrome. Brain and Development, 2020, 42, 720-729.	1.1	12
33	Treatment use among children with Tourette syndrome living in the United States, 2014. Psychiatry Research, 2020, 293, 113400.	3.3	6
34	Regional, not global, functional connectivity contributes to isolated focal dystonia. Neurology, 2020, 95, e2246-e2258.	1.1	23
35	Batten disease: an expert update on agents in preclinical and clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 1317-1322.	4.1	9
36	The President, Past President, Executive Director, and the Board of the Child Neurology Society Denounce Racism and Inequality. Annals of Neurology, 2020, 88, 209-210.	5.3	3

#	Article	IF	CITATIONS
37	The CLN3 Disease Staging System. Neurology, 2020, 94, e2436-e2440.	1.1	18
38	Reply. Journal of Pediatrics, 2019, 204, 326-327.	1.8	O
39	A novel, hybrid, single- and multi-site clinical trial design for CLN3 disease, an ultra-rare lysosomal storage disorder. Clinical Trials, 2019, 16, 555-560.	1.6	3
40	Children with Tourette Syndrome in the United States: Parent-Reported Diagnosis, Co-Occurring Disorders, Severity, and Influence of Activities on Tics. Journal of Developmental and Behavioral Pediatrics, 2019, 40, 407-414.	1.1	25
41	Reply. Journal of Pediatrics, 2019, 204, 324-325.	1.8	О
42	Quantitative, clinically relevant acoustic measurements of focal embouchure dystonia. Movement Disorders, 2018, 33, 449-458.	3.9	12
43	Phenotypes, genotypes, and the management of paroxysmal movement disorders. Developmental Medicine and Child Neurology, 2018, 60, 559-565.	2.1	31
44	Pharmacological and neurosurgical interventions for managing dystonia in cerebral palsy: a systematic review. Developmental Medicine and Child Neurology, 2018, 60, 356-366.	2.1	72
45	Basal ganglia mechanisms in action selection, plasticity, and dystonia. European Journal of Paediatric Neurology, 2018, 22, 225-229.	1.6	26
46	Alterations in vestibular function in individuals with cervical dystonia and the effects of botulinum toxin treatment. Basal Ganglia, 2018, 13, 1-6.	0.3	1
47	Motor sequence awareness is impaired in dystonia despite normal performance. Annals of Neurology, 2018, 83, 52-60.	5.3	1
48	Natural history data for childhood neurodegenerative disease. The Lancet Child and Adolescent Health, 2018, 2, 547-548.	5.6	3
49	A Pediatric Neurology Perspective on Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection and Pediatric Acute-Onset Neuropsychiatric Syndrome. Journal of Pediatrics, 2018, 199, 243-251.	1.8	42
50	Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal) Tj ETQq0 0 0	rgBT /Ove	erlock 10 Tf 50
51	Management Strategies for CLN2 Disease. Pediatric Neurology, 2017, 69, 102-112.	2.1	80
52	Screening tools for tic disorders-Focus on development or implementation?. Movement Disorders, 2017, 32, 946-946.	3.9	2
53	Correcting honest pervasive errors in the scientific literature. Neurology, 2017, 89, 11-13.	1.1	7
54	Classification of Movement Disorders. , 2016, , 27-35.		0

#	Article	IF	Citations
55	Functional (Psychogenic) Movement Disorders. , 2016, , 515-524.		O
56	<i><scp>GNAO</scp>1</i> â€Associated Movement Disorder. Movement Disorders Clinical Practice, 2016, 3, 615-617.	1.5	22
57	Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Molecular Genetics and Metabolism, 2016, 118, 65-69.	1.1	28
58	Remote Assessment of Cognitive Function in Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease). Journal of Child Neurology, 2016, 31, 481-487.	1.4	21
59	Advances in management of movement disorders in children. Lancet Neurology, The, 2016, 15, 719-735.	10.2	84
60	"Complex―dystonia is not a category in the new 2013 consensus classification. Movement Disorders, 2016, 31, 1758-1759.	3.9	5
61	Intravenous Immunoglobulin Is Not an Effective Treatment for Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection Obsessive-Compulsive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 837-838.	0.5	5
62	Report of a workshop on research gaps in the treatment of cerebral palsy. Neurology, 2016, 87, 1293-1298.	1.1	28
63	Management of movement disorders in children – Authors' reply. Lancet Neurology, The, 2016, 15, 1302-1303.	10.2	2
64	Cannabinoids in the treatment of movement disorders: A systematic review of case series and clinical trials. Basal Ganglia, 2016, 6, 173-181.	0.3	13
65	Temporal and kinematic consistency predict sequence awareness. Experimental Brain Research, 2016, 234, 3025-3036.	1.5	2
66	Pilot Testing Behavior Therapy for Chronic Tic Disorders in Neurology and Developmental Pediatrics Clinics. Journal of Child Neurology, 2016, 31, 444-450.	1.4	18
67	Basal Ganglia Anatomy, Biochemistry, and Physiology. , 2016, , 3-12.		1
68	Paroxysmal Dyskinesias. Journal of Pediatric Neurology, 2015, 13, 225-230.	0.2	2
69	Paroxysmal dyskinesias. Journal of Pediatric Neurology, 2015, 08, 065-067.	0.2	1
70	Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis. Developmental Medicine and Child Neurology, 2015, 57, 366-371.	2.1	24
71	SUICIDAL THOUGHTS AND BEHAVIORS IN CHILDREN AND ADOLESCENTS WITH CHRONIC TIC DISORDERS. Depression and Anxiety, 2015, 32, 744-753.	4.1	44
72	Treatment of Paroxysmal Dyskinesias in Children. Current Treatment Options in Neurology, 2015, 17, 350.	1.8	18

#	Article	IF	CITATIONS
73	Tourette syndrome deep brain stimulation: A review and updated recommendations. Movement Disorders, 2015, 30, 448-471.	3.9	236
74	Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates. Annals of Neurology, 2014, 76, 393-402.	5.3	58
75	The impact of development on the interpretation of movement disorders rating scales. Developmental Medicine and Child Neurology, 2014, 56, 511-512.	2.1	5
76	A National Profile of Tourette Syndrome, 2011–2012. Journal of Developmental and Behavioral Pediatrics, 2014, 35, 317-322.	1.1	90
77	Progress in research on Tourette syndrome. Journal of Obsessive-Compulsive and Related Disorders, 2014, 3, 359-362.	1.5	22
78	Experience, knowledge, and opinions about childhood genetic testing in Batten disease. Molecular Genetics and Metabolism, 2014, 111, 197-202.	1.1	11
79	Spatial Reorganization of Putaminal Dopamine D2-Like Receptors in Cranial and Hand Dystonia. PLoS ONE, 2014, 9, e88121.	2.5	17
80	Special concerns in defining, studying, and treating dystonia in children. Movement Disorders, 2013, 28, 921-925.	3.9	55
81	Dystonia rating scales: Critique and recommendations. Movement Disorders, 2013, 28, 874-883.	3.9	150
82	Enzyme Replacement in Neuronal Storage Disorders in the Pediatric Population. Current Treatment Options in Neurology, 2013, 15, 634-651.	1.8	4
83	Neurobehavioral Features and Natural History of Juvenile Neuronal Ceroid Lipofuscinosis (Batten) Tj ETQq1 1 0.78	4314 rgB1 1.4	 Qyerlock
84	Current controversies on the role of behavior therapy in Tourette syndrome. Movement Disorders, 2013, 28, 1179-1183.	3.9	87
85	A Trial of Scheduled Deep Brain Stimulation for Tourette Syndrome. JAMA Neurology, 2013, 70, 85.	9.0	96
86	Conversion disorder and mass psychogenic illness in child neurology. Annals of the New York Academy of Sciences, 2013, 1304, 40-44.	3.8	165
87	Methodology of clinical research in rare diseases: Development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates. Contemporary Clinical Trials, 2013, 35, 48-54.	1.8	22
88	NCL diseases â€" clinical perspectives. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1801-1806.	3.8	194
89	Phenomenology and classification of dystonia: A consensus update. Movement Disorders, 2013, 28, 863-873.	3.9	1,754
90	Clinical Trials in Rare Disease. Journal of Child Neurology, 2013, 28, 1142-1150.	1.4	155

#	Article	IF	Citations
91	Batten Disease. Journal of Child Neurology, 2013, 28, 1074-1100.	1.4	34
92	Classification and Natural History of the Neuronal Ceroid Lipofuscinoses. Journal of Child Neurology, 2013, 28, 1101-1105.	1.4	117
93	The Basal Ganglia. , 2013, , 653-676.		7
94	<i>ATP1A3</i> mutations in infants: a new rapidâ€onset dystonia–Parkinsonism phenotype characterized by motor delay and ataxia. Developmental Medicine and Child Neurology, 2012, 54, 1065-1067.	2.1	78
95	Thimerosal Exposure in Early Life and Neuropsychological Outcomes 7–10 Years Later. Journal of Pediatric Psychology, 2012, 37, 106-118.	2.1	33
96	Metabolic Encephalopathies. , 2012, , 153-161.		2
97	Neurologic Complications of Cardiac Surgery. , 2012, , 174-181.		1
98	Application of MR Diffusion, CT Angiography and Perfusion Imaging in Stroke Neurocritical Care. , 2012, , 205-213.		0
99	Females experience a more severe disease course in batten disease. Journal of Inherited Metabolic Disease, 2012, 35, 549-555.	3.6	54
100	Moving from PANDAS to CANS. Journal of Pediatrics, 2012, 160, 725-731.	1.8	101
101	Functional anatomy of the basal ganglia. , 2012, , 53-64.		0
102	Advances in understanding and treatment of Tourette syndrome. Nature Reviews Neurology, 2011, 7, 667-676.	10.1	145
103	Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease;) Tj ETQq $1\ 1\ 0.78$	1314 rgBT 3.6	/Overlock 10
104	Faulty brakes?. Neurology, 2011, 76, 592-593.	1.1	5
105	Acute Postinfectious Movement and Psychiatric Disorders in Children and Adolescents. Journal of Child Neurology, 2011, 26, 214-217.	1.4	11
106	Development of the Hypertonia Assessment Tool (HAT): a discriminative tool for hypertonia in children. Developmental Medicine and Child Neurology, 2010, 52, e83-7.	2.1	130
107	Definition and classification of hyperkinetic movements in childhood. Movement Disorders, 2010, 25, 1538-1549.	3.9	374
108	Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease). Developmental Medicine and Child Neurology, 2010, 52, 637-643.	2.1	24

#	Article	IF	CITATIONS
109	Movement Disorders II: Chorea, Dystonia, Myoclonus, and Tremor. Pediatrics in Review, 2010, 31, 287-295.	0.4	10
110	Basal Ganglia Anatomy, Biochemistry, and Physiology. , 2010, , 2-8.		1
111	Tics and Tourette Syndrome. , 2010, , 40-55.		0
112	Bilateral deep brain stimulation for treatment of medically refractory paroxysmal nonkinesigenic dyskinesia. Journal of Neurosurgery, 2010, 112, 847-850.	1.6	20
113	Movement Disorders I: Tics and Stereotypies. Pediatrics in Review, 2010, 31, 223-233.	0.4	5
114	Immune defenses of Xenopus laevis against Batrachochytrium dendrobatidis. Frontiers in Bioscience - Elite, 2009, 1, 68.	1.8	17
115	Pediatric Movement Disorders. , 2008, , 469-476.		0
116	Neuropsychological Symptoms of Juvenile-Onset Batten Disease: Experiences From 2 Studies. Journal of Child Neurology, 2007, 22, 621-627.	1.4	31
117	Paroxysmal dyskinesias. Current Opinion in Pediatrics, 2007, 19, 652-656.	2.0	12
118	Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children With Secondary Dystonia due to Cerebral Palsy. Journal of Child Neurology, 2007, 22, 530-537.	1.4	243
119	Reply: Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Movement Disorders, 2007, 22, 1367-1368.	3.9	2
120	DEEP BRAIN STIMULATION. Annual Review of Neuroscience, 2006, 29, 229-257.	10.7	820
121	Recent advances in Tourette syndrome research. Trends in Neurosciences, 2006, 29, 175-182.	8.6	436
122	Standardized assessment of behavior and adaptive living skills in juvenile neuronal ceroid lipofuscinosis. Developmental Medicine and Child Neurology, 2006, 48, 259-264.	2.1	18
123	Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx, 2006, 3, 192-206.	6.0	273
124	New treatments for tic disorders. Current Treatment Options in Neurology, 2006, 8, 465-473.	1.8	11
125	Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Movement Disorders, 2006, 21, 1831-1838.	3.9	238
126	Definition and Classification of Negative Motor Signs in Childhood. Pediatrics, 2006, 118, 2159-2167.	2.1	226

#	Article	IF	CITATIONS
127	Functional Anatomy of the Basal Ganglia. Medical Psychiatry, 2006, , 45-56.	0.2	O
128	Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs. Advances in Neurology, 2006, 99, 89-98.	0.8	112
129	Microinfusion of antineuronal antibodies into rodent striatum: Failure to differentiate between elevated and low titers. Journal of Neuroimmunology, 2005, 163, 8-14.	2.3	44
130	Masturbation in Infancy and Early Childhood Presenting as a Movement Disorder: 12 Cases and a Review of the Literature. Pediatrics, 2005, 116, 1427-1432.	2.1	87
131	Psychogenic movement disorders in children. Pediatric Neurology, 2004, 30, 1-6.	2.1	54
132	Basal Ganglia Circuits and Thalamocortical Outputs. Neurological Disease and Therapy, 2004, , 253-272.	0.0	0
133	Dysfunction of dopaminergic pathways in dystonia. Advances in Neurology, 2004, 94, 163-70.	0.8	65
134	Dopa-responsive dystonia in children. Current Treatment Options in Neurology, 2003, 5, 279-282.	1.8	14
135	Classification and Definition of Disorders Causing Hypertonia in Childhood. Pediatrics, 2003, 111, e89-e97.	2.1	641
136	The Basal Ganglia and Involuntary Movements. Archives of Neurology, 2003, 60, 1365.	4. 5	487
137	Progressive myoclonus in a child with a deep cerebellar mass. Neurology, 2003, 61, 829-831.	1.1	29
138	Movement Disorders in Children. Pediatrics in Review, 2003, 24, 39-51.	0.4	8
139	Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2002, 14, 438-442.	1.8	37
140	Basal ganglia dysfunction in Tourette's syndrome: a new hypothesis. Pediatric Neurology, 2001, 25, 190-198.	2.1	331
141	Thalamic stimulation for primary writing tremor. Journal of Neurology, 2001, 248, 380-382.	3.6	41
142	Motor benefit from levodopa in spastic quadriplegic cerebral palsy. Annals of Neurology, 2000, 47, 662-665.	5.3	35
143	Response to levodopa challenge in Tourette syndrome. Movement Disorders, 2000, 15, 1194-1198.	3.9	52
144	Impaired Reaching and Grasping After Focal Inactivation of Globus Pallidus Pars Interna in the Monkey. Journal of Neurophysiology, 1999, 82, 2049-2060.	1.8	50

#	Article	IF	CITATIONS
145	Posterior vermal split syndrome. Annals of Neurology, 1998, 44, 601-610.	5.3	91
146	Letters to the Editor. Movement Disorders, 1998, 13, 980-982.	3.9	4
147	THE BASAL GANGLIA: FOCUSED SELECTION AND INHIBITION OF COMPETING MOTOR PROGRAMS. Progress in Neurobiology, 1996, 50, 381-425.	5.7	2,258
148	Basal ganglia intrinsic circuits and their role in behavior. Current Opinion in Neurobiology, 1993, 3, 950-957.	4.2	282
149	Preferential relation of pallidal neurons to ballistic movements. Brain Research, 1987, 417, 393-398.	2.2	21
150	Activity of basal forebrain neurons in the rat during motivated behaviors. Behavioural Brain Research, 1983, 8, 85-108.	2.2	39
151	The Rise of Functional Tic-Like Behaviors: What Do the COVID-19 Pandemic and Social Media Have to Do With It? A Narrative Review. Frontiers in Pediatrics, 0, 10, .	1.9	15